ArticleClinical, cosmetic and investigational dermatology2026
Thermoresponsive Hydroxybutyl Chitosan-Assisted Carteolol Delivery with Pulsed Dye Laser for Superficial Infantile Hemangiomas: An Exploratory Randomized Study.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To preliminarily evaluate a thermoresponsive hydroxybutyl chitosan (HBC)-assisted topical carteolol delivery regimen combined with pulsed dye laser (PDL), compared with conventional carteolol wet-compress therapy combined with PDL, in infants with superficial infantile hemangiomas. Patients and Methods: This single-center, open-label, randomized exploratory study included 40 infants with superficial IHs, who were assigned to an HBC group or a control group at a 1:1 ratio. Both groups received PDL. The HBC group received immediate post-laser topical application of the optimized HBC-carteolol mixture, whereas the control group received conventional topical carteolol wet-compress therapy after PDL. The predefined efficacy assessment was performed at the 6-month visit, while clinical follow-up continued for 6 to 12 months as routine clinical follow-up. The primary endpoint was the number of PDL treatment sessions completed during the 6-month treatment period. Secondary outcomes included 6-month Hemangioma Activity Score (HAS), change in HAS from baseline to 6 months, and treatment-related complications. Results: At the predefined 6-month assessment, the HBC group required fewer treatment sessions than the control group during the 6-month treatment period (3.5 ± 0.6 vs 4.7 ± 0.7, P < 0.001). The 6-month HAS was numerically lower in the HBC group than in the control group, but the difference was not statistically significant (0.3 ± 0.4 vs 0.4 ± 0.4, P = 0.272). The HAS change score also did not differ significantly between groups (4.6 ± 0.5 vs 4.5 ± 0.5, P = 0.440). The aggregate treatment-related local complication rate was lower in the HBC group than in the control group (5.0% vs 35.0%, P = 0.048). Conclusion: In this single-center exploratory randomized study, the HBC-carteolol-PDL regimen was associated with fewer treatment sessions and complications than conventional carteolol wet-compress therapy combined with PDL. Further component-controlled studies are needed to determine the independent effect of HBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.